PMLiVE10d
Innovation and flexibility in long-term follow-up studies
Post-treatment follow-up of patients is not new. Traditional follow-up studies may last two to five years, while long-term follow-up (LTFU) studies can last from 15 years to a lifetime. Cell and gene ...
PMLiVE5d
Sanofi shares positive late-stage results for investigational BTK inhibitor in progressive MS
Sanofi has shared positive results from a late-stage study of its investigational BTK inhibitor, tolebrutinib, in patients ...
PMLiVE4d
Ipsen’s Iqirvo receives EC approval to treat primary biliary cholangitis in adults
Ipsen’s Iqirvo (elafibranor) has been conditionally approved by the European Commission (EC) to treat primary biliary ...
PMLiVE5d
J&J’s Rybrevant combination approved by FDA to treat EGFR-mutated NSCLC
Rybrevant (amivantamab-vmjw) has been approved by the US Food and Drug Administration (FDA) as part of a combination ...
PMLiVE9d
Daiichi Sankyo’s Vanflyta recommended by NICE for acute myeloid leukaemia
Daiichi Sankyo’s Vanflyta (quizartinib) has been recommended by the National Institute for Health and Care Excellence (NICE) for certain cases of acute myeloid leukaemia (AML). The drug has been ...
PMLiVE9d
Merck presents positive phase 3 results for Keytruda regimen in early-stage breast cancer
Merck & Co – known as MSD outside the US and Canada – has shared positive overall survival (OS) results from a late-stage ...
PMLiVE12d
Eli Lilly announces FDA approval for Ebglyss in moderate-to-severe atopic dermatitis
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved its targeted IL-13 inhibitor Ebglyss (lebrikizumab-lbkz) to treat moderate-to-severe atopic dermatitis (AD). The ...
PMLiVE12d
Roche’s injectable PD-L1 inhibitor granted FDA approval for multiple cancer types
Roche’s injectable PD-L1 inhibitor Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) has been approved by the US Food and Drug Administration (FDA) for multiple cancer types. The subcutaneous ...
PMLiVE8d
Merck/Daiichi Sankyo’s ADC candidate shows promise in phase 3 lung cancer trial
Merck & Co – known as MSD outside the US and Canada – and Daiichi Sankyo have announced that a late-stage trial of patritumab deruxtecan in non-small cell lung cancer (NSCLC) met its primary endpoint ...
PMLiVE11d
Sanofi/Regeneron’s Dupixent receives FDA approval for adolescents with CRSwNP
Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) as an add-on maintenance treatment for adolescents with chronic rhinosinusitis with nasal ...
PMLiVE12d
Merck shares positive ten-year results for Keytruda in advanced melanoma
Merck & Co – known as MSD outside the US and Canada – has shared positive ten-year results from a late-stage study of its anti-PD-1 therapy Keytruda (pembrolizumab) in melanoma. The open-label KEYNOTE ...
PMLiVE10d
J&J’s Rybrevant combination shows positive overall survival trend in late-stage lung cancer study
Johnson & Johnson’s (J&J) Rybrevant (amivantamab-vmjw) combination has demonstrated a positive overall survival trend in adults with lung cancer, according to new late-stage results shared by the ...